GlyTherix Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $6.55M

  • Investors
  • 6

GlyTherix General Information

Description

Developer of a targeted radiotherapy platform designed to treat solid tumors by delivering antibody radiopharmaceuticals. The company offers a proprietary antibody, which targets Glypican-1 found only in tumor tissue, enabling patients with prostate, bladder, pancreatic, glioblastoma, oesophageal, and ovarian cancers access to new treatment options where few exist.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Level 1, 3 Innovation Road
  • Macquarie Park, New South Wales 2113
  • Australia
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • Level 1, 3 Innovation Road
  • Macquarie Park, New South Wales 2113
  • Australia

GlyTherix Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GlyTherix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series A1) 16-Feb-2024 $6.55M Completed Clinical Trials - Phase 1
5. Accelerator/Incubator 13-Oct-2023 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series A) 22-Jul-2023 Completed Pre-Clinical Trials
3. Grant 01-Dec-2021 Completed Pre-Clinical Trials
2. Grant 16-Jul-2020 $2.07M Completed Startup
1. Accelerator/Incubator Completed Startup
To view GlyTherix’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

GlyTherix Patents

GlyTherix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2026908908-A0 Stable anti-gpc-1 antibodies and uses thereof Pending 27-Oct-2026
AU-2025904740-A0 Stable anti-gpc-1 antibodies and uses thereof Pending 10-Oct-2025
AU-2024903281-A0 Stable anti-gpc-1 antibodies and uses thereof Inactive 11-Oct-2024
AU-2023903279-A0 Stable anti-gpc-1 antibodies and uses thereof Inactive 13-Oct-2023
AU-2022903168-A0 Stable anti-gpc-1 antibodies and uses thereof Inactive 26-Oct-2022
To view GlyTherix’s complete patent history, request access »

GlyTherix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GlyTherix Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Endless Frontier Labs Accelerator/Incubator
Cyclowest Corporation Minority
NSW Government (Energy) Government
Therapeutic Innovations Australia Corporation
Cooperative Research Centres Projects Government
You’re viewing 5 of 6 investors. Get the full list »

GlyTherix FAQs

  • When was GlyTherix founded?

    GlyTherix was founded in 2017.

  • Where is GlyTherix headquartered?

    GlyTherix is headquartered in Macquarie Park, Australia.

  • What is the size of GlyTherix?

    GlyTherix has 8 total employees.

  • What industry is GlyTherix in?

    GlyTherix’s primary industry is Biotechnology.

  • Is GlyTherix a private or public company?

    GlyTherix is a Private company.

  • What is GlyTherix’s current revenue?

    The current revenue for GlyTherix is .

  • How much funding has GlyTherix raised over time?

    GlyTherix has raised $6.55M.

  • Who are GlyTherix’s investors?

    Endless Frontier Labs, Cyclowest, NSW Government (Energy), Therapeutic Innovations Australia, and Cooperative Research Centres Projects are 5 of 6 investors who have invested in GlyTherix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process